Henlius Biotech's Gets US FDA Nod for Trial of Tumor Drug
MT Newswires Live
Sep 08
Shanghai Henlius Biotech's (HKG:2696) investigational new drug application for the phase I clinical trial of HLX17 was approved by the United States Food and Drug Administration (FDA), a Monday Hong Kong bourse filing said.
The international multi-center clinical trial will be conducted in patients with multiple resected solid tumours.
The potential indications of HLX17, which is a biosimilar of pembrolizumab, include melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell cancer, and various other cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.